MX2021015993A - Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico. - Google Patents

Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico.

Info

Publication number
MX2021015993A
MX2021015993A MX2021015993A MX2021015993A MX2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A MX 2021015993 A MX2021015993 A MX 2021015993A
Authority
MX
Mexico
Prior art keywords
combination
gilteritinib
venetoclax
midostaurin
azacitidine
Prior art date
Application number
MX2021015993A
Other languages
English (en)
Inventor
Kyle Macbeth
De Menezes Daniel E Lopes
Yumin Dai
Mark Frattini
Cl Beach
Shelonitda Rose
Diana R Dunshee
Jessica Jang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021015993A publication Critical patent/MX2021015993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

En el presente documento se proporcionan métodos para usar 5-azacitidina en combinación con uno o más agentes adicionales para tratar enfermedades y trastornos que incluyen leucemia mieloide o mielógena aguda (LMA). Otras enfermedades y trastornos asociados con proliferación celular anormal, síndromes mielodisplásicos (SMD), proliferación celular anormal, trastornos hematológicos y trastornos inmunitarios, entre otros.
MX2021015993A 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico. MX2021015993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864413P 2019-06-20 2019-06-20
PCT/US2020/038760 WO2020257665A1 (en) 2019-06-20 2020-06-19 Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
MX2021015993A true MX2021015993A (es) 2022-04-06

Family

ID=71528047

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021015993A MX2021015993A (es) 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico.
MX2021015992A MX2021015992A (es) 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015992A MX2021015992A (es) 2019-06-20 2020-06-19 Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.

Country Status (11)

Country Link
US (2) US20220249528A1 (es)
EP (2) EP3986403A1 (es)
JP (2) JP2022537384A (es)
KR (2) KR20220024639A (es)
CN (2) CN115066243A (es)
AU (2) AU2020296179A1 (es)
BR (2) BR112021025537A2 (es)
CA (2) CA3143711A1 (es)
IL (2) IL289115A (es)
MX (2) MX2021015993A (es)
WO (2) WO2020257665A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597741A1 (en) 2012-04-27 2020-01-22 Duke University Genetic correction of mutated genes
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
WO2022187288A2 (en) * 2021-03-01 2022-09-09 Duke University Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
AU2022273023A1 (en) * 2021-05-11 2023-11-23 Abbvie Inc. Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine
CN117651556A (zh) * 2021-05-11 2024-03-05 艾伯维公司 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969144T3 (es) * 2008-05-15 2024-05-16 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
AR100251A1 (es) 2014-05-01 2016-09-21 Celgene Quanticel Res Inc Inhibidores de la dematilasa-1 especifica de lisina
SG10202008486SA (en) * 2014-09-05 2020-09-29 Celgene Quanticel Research Inc Inhibitors of lysine specific demethylase-1
MX2018005620A (es) * 2015-11-05 2018-08-01 Celgene Quanticel Res Inc Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina.
SG11201807972YA (en) * 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
US20200069677A1 (en) * 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination for cancer treatment
UY38511A (es) * 2018-12-18 2020-07-31 Argenx Bvba Terapia de combinación cd70

Also Published As

Publication number Publication date
CN115066243A (zh) 2022-09-16
CN114727996A (zh) 2022-07-08
US20220249528A1 (en) 2022-08-11
AU2020297596A1 (en) 2022-02-03
BR112021025537A2 (pt) 2022-03-03
JP2022537384A (ja) 2022-08-25
KR20220024639A (ko) 2022-03-03
EP3986403A1 (en) 2022-04-27
WO2020257665A1 (en) 2020-12-24
CA3143719A1 (en) 2020-12-24
US20220249529A1 (en) 2022-08-11
WO2020257671A1 (en) 2020-12-24
AU2020296179A1 (en) 2022-02-03
EP3986404A1 (en) 2022-04-27
IL289110A (en) 2022-02-01
IL289115A (en) 2022-02-01
BR112021025375A2 (pt) 2022-02-01
JP2022537551A (ja) 2022-08-26
CA3143711A1 (en) 2020-12-24
KR20220050874A (ko) 2022-04-25
MX2021015992A (es) 2022-04-06

Similar Documents

Publication Publication Date Title
MX2021015993A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para el tratamiento de leucemia o síndrome mielodisplásico.
MX2022004370A (es) Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
MX2023005326A (es) Composiciones de oligonucleótidos y métodos de las mismas.
CR7804A (es) Terapia combinada para el tratamiento de leucemia aguda y sindrome mielodisplasico
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
WO2014190163A3 (en) Combination therapy for mds
ATE418991T1 (de) Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
PH12019502477A1 (en) Use of anti cd70 antibody argx-10 treat acute myeloid leukemia
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
MX2017014001A (es) Analogos de nucleosidos 5 ' -sustituidos.
SI1866324T1 (sl) Fosforamidni derivati nukleotidnih sestavkov za uporabo pri zdravljenju raka
MX2007005179A (es) Formas de dosificacion.
RU2013102398A (ru) Лечение рака крови
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
WO2020191326A8 (en) Treatment of acute myeloid leukemia (aml) with venetoclax failure
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2023013364A (es) Regimenes de dosificacion de venetoclax para usarse en el tratamiento de los sindromes mielodisplasicos en combinacion con azacitidina.
MX2017011882A (es) Composiciones y metodos para focalizar cd99 en malignidades hematopoyeticas y linfoides.
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
EA201600133A1 (ru) Воласертиб в комбинации с децитабином для лечения острого миелоидного лейкоза и миелодиспластического синдрома
MX2023008016A (es) Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
MD3630177T2 (ro) Paradigmă de tratament pentru un tratament combinat cu anticorpi anti-CD19 și venetoclax
PA8655401A1 (es) Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10